Author(s): Isabelle Gomez

Surgery is a vital component of pancreatic cancer treatment that must be completed to attain cure potential. Multimodal treatment for pancreatic cancer must combine both surgery and chemotherapy to attain curative potential. Despite advancements in surgical procedures and perioperative care, it is still considered a high-risk surgery with a high rate of postoperative morbidity. To generate solid and uniform outcome references after pancreatic-duodenectomy, several criteria have been established. The novel notion behind using the benchmark concept to surgery is to analyze the best possible outcomes in a well-defined low-risk patient group to generate meaningful comparative data. Longer procedures have been required as a result of more effective chemotherapy and recent developments in surgical abilities, pushing the boundaries of respectability. Multivisceral resections, with or without resection of major mesenteric arteries, are now being performed in an increasing number of patients, and they are associated with improved overall survival and/or patient-reported outcomes.